Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04292223
Other study ID # ACP-103-063
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date February 10, 2020
Est. completion date April 26, 2022

Study information

Verified date August 2022
Source ACADIA Pharmaceuticals Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To assess the effect of pimavanserin on the activities of daily living in subjects with Parkinson's Disease Psychosis


Description:

This study will be conducted as a 16-week, multi-center, single-arm, open-label study. Pimavanserin will be administered at a dose of 34 mg to approximately 50 subjects with PDP


Recruitment information / eligibility

Status Completed
Enrollment 29
Est. completion date April 26, 2022
Est. primary completion date April 26, 2022
Accepts healthy volunteers No
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria: 1. Male or female subjects at least 40 years of age 2. Has a Mini-Mental State Examination (MMSE) score =19 at Screening 3. Has a diagnosis of idiopathic Parkinson's disease (PD) 4. Has psychotic symptoms that may impair function and are severe enough to warrant treatment with an antipsychotic agent 5. Psychotic symptoms developed after the onset of symptoms of PD 6. If the subject is female, she must not be pregnant or breastfeeding. She must also be of non-childbearing potential (defined as either surgically sterilized or at least 1 year postmenopausal) OR must agree to use TWO clinically acceptable methods of contraception. Exclusion Criteria: 1. Has atypical parkinsonism (Parkinson's plus, multiple system atrophy [MSA], progressive supranuclear palsy [PSP]), or secondary parkinsonism variants such as tardive or medication induced parkinsonism 2. Has undergone ablative procedures such as a pallidotomy, thalamotomy, or treatment with focused ultrasound, or has an implanted deep brain stimulator 3. Has current evidence of an unstable neurological, cardiovascular, respiratory, gastrointestinal, renal, hepatic, hematologic, or other medical or psychiatric disorder, including cancer or malignancies that, in the judgment of the Investigator, would jeopardize the safe participation of the subject in the study or significantly interfere with the conduct or interpretation of the study 4. Has a history of myocardial infarction, unstable angina, acute coronary syndrome, or cerebrovascular accident within the last 6 months prior to Screening 5. Has any of the following: 1. greater than New York Heart Association (NYHA) Class 2 congestive heart failure 2. Grade 2 or greater angina pectoris (by Canadian Cardiovascular Society Angina Grading Scale) 3. sustained ventricular tachycardia 4. ventricular fibrillation 5. torsades de pointes 6. syncope due to an arrhythmia 7. an implantable cardiac defibrillator 6. Has a known personal or family history of long QT syndrome or family history of sudden cardiac death 7. Requires treatment with a medication or other substance that is prohibited by the protocol 8. Has a body mass index (BMI) <18.5 kg/m2 or >35 kg/m2 at Screening or Baseline or known unintentional clinically significant weight loss (i.e., =7%) over past 6 months 9. Is suicidal at Screening or Baseline 10. Has a history of a significant psychotic disorder prior to or concomitantly with the onset of PD including, but not limited to, schizophrenia or bipolar disorder 11. Had dementia prior to or concomitantly with the onset of motor symptoms of PD 12. Positive COVID-19 polymerase chain reaction (PCR) or antigen result in the last 2 weeks prior to screening 13. Is judged by the Investigator or the Medical Monitor to be inappropriate for the study for any reason Additional inclusion/exclusion criteria apply. Subjects will be evaluated at screening to ensure that all criteria for study participation are met.

Study Design


Intervention

Drug:
Pimavanserin
Pimavanserin 34 mg (provided as 1×34 mg capsule), administered orally, once daily for 16 weeks

Locations

Country Name City State
United States AU Movement and Memory Disorders Augusta Georgia
United States Neurological Associates of North Texas Dallas Texas
United States Neurology Diagnostics, Inc. Dayton Ohio
United States Wentworth Health Partners Coastal Neurology Services Dover New Hampshire
United States KCA Neurology Franklin Tennessee
United States Neurology Center of North Orange County Fullerton California
United States Premier Clinical Research Institute, Inc. Miami Florida
United States Global Health Research Center, Inc. Miami Lakes Florida
United States The Orthopedic Foundation New Albany Ohio
United States Quantum Laboratories, Inc. Pompano Beach Florida
United States Parkinson's Disease Treatment Center of Southwest Florida Port Charlotte Florida
United States Accel Research Sites - Brain and Spine Institute Port Orange Florida
United States Maine Medical Partners Neurology Scarborough Maine
United States Movement Disorders Center of Arizona Scottsdale Arizona
United States Infinity Clinical Research, LLC Sunrise Florida
United States Bio Behavioral Health Toms River New Jersey
United States Central States Research Tulsa Oklahoma
United States Premiere Research Institute at Palm Beach Neurology West Palm Beach Florida

Sponsors (1)

Lead Sponsor Collaborator
ACADIA Pharmaceuticals Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline (Week 0) to Week 16 on the modified Functional Status Questionnaire (mFSQ) total score The mFSQ is a self-administered questionnaire that provides assessment in ambulatory patients of physical, psychological, social, and role function. It comprises 34 core items that produces 6 summary scale scores:
Basic activities of daily living
Intermediate activities of daily living
Psychological function and mental health
Social/Role function
Work performance
Social activity
Quality interaction It also includes 6 single-item scores (work situation; days per month in bed due to illness or injury; days per month when illness injury reduced activities normally performed for half a day; satisfaction with sexual relationship; satisfaction with own health; frequency of social interaction)
16 weeks
Secondary Change from baseline to Week 16 on the Schwab and England ADL Scale (Caregiver and Patient Version) The Schwab & England ADL Scale is widely used in PD. It is rated by physicians, patients, or staff using a 0% to 100% scale with 10% intervals, where 100% is "Completely independent. Unaware of difficulty" and 0% is "Vegetative functions such as swallowing, bladder and bowel functions are not functioning. Bedridden" 16 Weeks
Secondary Change from baseline to Week 16 on the Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I and II (Caregiver and Patient Version) The MDS-UPDRS is a comprehensive battery of motor and behavioral indices derived from the Columbia Scale (Fahn et al. 1987). The MDS-UPDRS Parts I and II will be used to assess mentation, behavior and mood (Part 1) and activities of daily living (Part II) and are rater-based examinations consisting of 4 and 13 items, respectively. 16 Weeks
Secondary Week 16 Clinical Global Impression - Improvement (CGI-I) score for hallucinations and delusions The CGI-I is a clinician-rated, 7-point scale that is designed to rate the improvement in the subject's symptoms at the time of assessment, relative to the symptoms at Baseline (Guy 1976). Severity ratings should be based on the behavioral domains of clinical concern, namely hallucinations and delusions. 16 Weeks
Secondary Change from Baseline to Week 16 on the Clinical Global Impression - Severity of Illness (CGI-S) score for hallucinations and delusions The CGI-S scale is a clinician-rated, 7-point scale that is designed to rate the severity of the subject's neuropsychiatric symptoms at the time of assessment using the Investigator's judgment and past experience with subjects who have the same disorder (Guy 1976). Severity ratings should be based on the behavioral domains of clinical concern, namely hallucinations and delusions. 16 Weeks
Secondary Week 16 on the Patient Global Impression of Improvement (PGI-I) score for hallucinations and delusions The PGI-I is a global index used to rate the response of a condition to a therapy. It is a simple, direct, easy to use scale that is intuitively understandable to subjects and clinicians. The PGI-I asks the patient to rate their symptoms now, as compared with how it was at Baseline before beginning treatment, ranging from 1=very much better to 7=very much worse. Severity ratings should be based on the behavioral domains of clinical concern, namely hallucinations and delusions. 16 Weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05824728 - Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis Phase 2
Terminated NCT03152292 - The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study
Withdrawn NCT05344365 - A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis Phase 2
Recruiting NCT05357612 - Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases Phase 4
Completed NCT06450184 - Bioequivalence Study of Pimavanserin 34 mg Capsule Phase 1
Completed NCT02969369 - A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis Phase 2
Not yet recruiting NCT05995782 - A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418 Phase 1
Recruiting NCT04592965 - Hallucinations in Parkinson's Disease N/A
Recruiting NCT04579887 - Presence Hallucination in Parkinson's Disease N/A
Completed NCT05240339 - Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD)
Recruiting NCT03661125 - SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis Early Phase 1